logo-loader
viewErgomed PLC

Ergomed team discuss new coronavirus project and 'transformational 2019'

Proactive London's Andrew Scott speaks to Ergomed PLC's (LON:ERGO) chief financial officer Richard Barfield and head of clinical development Dr Gordana Tonkovic.

The firm's involved in a study at the Papa Giovanni XXIII Hospital in Bergamo, in Italy where the siltuximab antibody is being trialled in the treatment of patients with serious respiratory complications caused by COVID-19.

Ergomed's also had its results out this morning for 2019 which revealed £68.3mln of revenue for the twelve months ended 31 December, up 26.1%.

Quick facts: Ergomed PLC

Price: 435 GBX

AIM:ERGO
Market: AIM
Market Cap: £209.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Ergomed PLC named herein, including the promotion by the Company of Ergomed PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 makes positive start to trading despite further...

Headlines from the Proactive UK newsroom. Oil prices have dropped further after Saudi Arabia and Russia postponed a meeting to discuss production cuts. The two countries started an oil price war last month. Rolls-Royce has built a cash pile of £6.7bn in anticipation of a further...

on 6/4/20

2 min read